Tumor Testing

Our paired tumor/germline testing gives clinicians the complete picture to clearly guide a patient’s healthcare decisions for somatic and germline mutations in a single test.




When you need to rule out or confirm Lynch syndrome or determine immunotherapy treatment eligibility in order to guide a patient’s next steps, you need a test that gives you the most comprehensive information possible. TumorNext-Lynch is a single test that looks at both tumor and germline mutations, giving you clearer information to better guide treatment and management decisions.

Download TumorNext-Lynch Product Summary


Women with epithelial ovarian cancer need a reliable test to determine if they are eligible for PARP inhibitor treatment. It may also be helpful to know if they are at risk for other cancers. TumorNext-HRD looks at both tumor and germline so that you can get the complete picture and provide timely targeted treatment to patients at a time when they need it most.

Download TumorNext-HRD Product Summary